Toronto Dominion Bank Boosts Stake in Insulet Co. (NASDAQ:PODD)

Toronto Dominion Bank raised its holdings in Insulet Co. (NASDAQ:PODD - Free Report) by 55.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 36,486 shares of the medical instruments supplier's stock after acquiring an additional 12,984 shares during the quarter. Toronto Dominion Bank owned about 0.05% of Insulet worth $9,526,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Horizon Investments LLC increased its position in Insulet by 3.1% during the fourth quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier's stock worth $362,000 after acquiring an additional 42 shares during the period. Wilmington Savings Fund Society FSB boosted its stake in shares of Insulet by 9.6% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier's stock valued at $140,000 after purchasing an additional 47 shares in the last quarter. Envestnet Portfolio Solutions Inc. boosted its stake in shares of Insulet by 2.3% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier's stock valued at $552,000 after purchasing an additional 48 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its position in Insulet by 5.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,050 shares of the medical instruments supplier's stock worth $274,000 after buying an additional 50 shares in the last quarter. Finally, Sequoia Financial Advisors LLC lifted its position in Insulet by 2.4% during the 4th quarter. Sequoia Financial Advisors LLC now owns 2,170 shares of the medical instruments supplier's stock worth $566,000 after buying an additional 50 shares in the last quarter.

Insulet Price Performance

PODD traded down $0.03 during trading on Monday, reaching $325.00. 712,029 shares of the company were exchanged, compared to its average volume of 706,872. The company's 50-day moving average is $277.81 and its two-hundred day moving average is $272.24. The company has a market cap of $22.87 billion, a price-to-earnings ratio of 56.13, a P/E/G ratio of 3.62 and a beta of 1.26. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12-month low of $172.07 and a 12-month high of $329.33.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm had revenue of $569.00 million for the quarter, compared to analysts' expectations of $543.20 million. During the same quarter last year, the firm posted $0.73 EPS. The company's revenue was up 28.8% compared to the same quarter last year. Research analysts forecast that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the sale, the senior vice president now owns 23,180 shares in the company, valued at approximately $7,382,134.60. This trade represents a 18.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now owns 3,231 shares of the company's stock, valued at $888,525. The trade was a 36.10% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have issued reports on PODD. Raymond James restated an "outperform" rating and set a $360.00 target price (up from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Barclays upped their price target on Insulet from $234.00 to $266.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 30th. Citigroup reissued a "buy" rating and set a $380.00 target price (up from $320.00) on shares of Insulet in a research note on Thursday, May 22nd. Oppenheimer increased their target price on Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Finally, Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Three equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $318.41.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.